Investor focus turns to Denali Therapeutics after trial setback

Denali Therapeutics (DNLI) is back in focus after a Phase 2b study failed, prompting investors to reassess the stock around its remaining neurodegenerative and lysosomal disease pipeline, as highlighted by Morgan Stanley.

Despite the recent trial setback, Denali Therapeutics' 1 day share price return of 3.66% and 7 day share price return of 8.55% suggest short term buying interest. However, the 5 year total shareholder return, down 67.52%, shows longer term holders have faced significant volatility.

If this kind of sharp sentiment shift has your attention, it can be useful to compare Denali with other healthcare focused AI opportunities using the 35 healthcare AI stocks

So with Denali Therapeutics trading at US$20.95 after a failed trial, a loss-making profile, mixed long term returns, and a sizeable gap to analyst targets, is this a genuine opportunity or a stock that already reflects expectations for future growth in its price?

Preferred Price to Book Multiple of 3.6x: Is it justified?

On a P/B of 3.6x, Denali Therapeutics trades below the 9x peer average flagged by one valuation check, yet above the 2.7x broader US biotech benchmark. This leaves a mixed picture for investors weighing the recent trial news against current pricing.

P/B compares the company’s market value to its net assets, which can be useful for loss making biopharma stocks where earnings are not yet a guide. For Denali, this ratio effectively shows how much investors are paying for each dollar of book equity that underpins a pipeline focused on neurodegenerative and lysosomal storage diseases.

The data suggests the stock screens as good value versus its direct peer group, where P/B sits at 9x, but looks more expensive than the wider US biotechs industry at 2.7x. That contrast indicates investors are paying a premium to the sector, possibly for Denali’s specific pipeline and forecasts, yet at a discount to closer peers that may be viewed as further along or perceived as lower risk.

Result: Price-to-book of 3.6x (ABOUT RIGHT)

However, investors still face clear risks, including Denali’s current loss of US$508.017 million and the possibility of further clinical setbacks across its early stage programs.

Another view using the SWS DCF model

The SWS DCF model points in the opposite direction to the earlier P/B check, with an estimated future cash flow value of $16.31 versus the current $20.95 share price. That suggests the stock could be pricing in more optimism than this cash flow view supports. Which signal do you trust more right now?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly mixed throughout this article, now is a good time to check the underlying data yourself and decide what really matters for your portfolio. To balance the concerns and potential upsides, take a closer look at the 1 key reward and 2 important warning signs

Ready to find your next investment idea?

Do not stop with one stock story. Use the Simply Wall St screener to uncover other opportunities that fit your goals before the market moves without you.

• Spot potential bargains early by scanning a curated set of 46 high quality undervalued stocks that combine quality fundamentals with appealing prices.
• Build a more resilient portfolio by focusing on 64 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• Stay ahead of the crowd by hunting through a screener containing 22 high quality undiscovered gems that highlights quality businesses still flying under most investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.